UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

__________________

 

FORM 8-A

 

FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES

PURSUANT TO SECTION 12(b) OR 12(g) OF THE

SECURITIES EXCHANGE ACT OF 1934

__________________

 

DIAMEDICA THERAPEUTICS INC.

(Exact name of registrant as specified in its charter)

 

Canada

Not Applicable

(State or other jurisdiction of incorporation or organization)

(I.R.S. Employer Identification Number)
   

2 Carlson Parkway, Suite 260

Minneapolis, Minnesota

 

55447

(Address of principal executive offices)

(Zip Code)

 

Securities to be registered pursuant to Section 12(b) of the Act:

 

Title of each class

to be so registered

  

Name of each exchange on which

each class is to be registered

Voting Common Shares,

no par value per share

(including the accompanying

Voting Common Share Purchase Rights)

  

The Nasdaq Stock Market LLC

 

If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c), check the following box: ☒

 

If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d), check the following box: ☐

 

Securities Act registration statement file number to which this form relates: 333-228313

 

Securities to be registered pursuant to Section 12(g) of the Act: None.

 

 

 
 

 

EXPLANATORY NOTE

 

Item 1. Description of Registrant’s Securities to Be Registered.

 

DiaMedica Therapeutics Inc. (the “Registrant”) hereby incorporates by reference the information set forth under the heading “Description of Share Capital” in the Registrant’s Registration Statement on Form S-1 (File No. 333-228313), as originally filed with the Securities and Exchange Commission (the “SEC”) on November 9, 2018, as amended (the “Registration Statement”), and in the prospectus included in the Registration Statement to be filed separately by the Registrant with the SEC pursuant to Rule 424(b) under the United States Securities Act of 1933, as amended, which prospectus shall be deemed to be incorporated by reference herein.

 

Item 2. Exhibits.

 

Pursuant to the Instructions as to Exhibits for Form 8-A, no exhibits are required to be filed because no other securities of the Registrant are registered on The Nasdaq Stock Market LLC and the securities registered hereby are not being registered pursuant to Section 12(g) of the United States Securities Exchange Act of 1934, as amended.

 

2
 

 

SIGNATURE

 

 

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the Registrant has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  DIAMEDICA THERAPEUTICS INC.
   
   
  By: /s/ Rick Pauls
   

Rick Pauls

President and Chief Executive Officer

 

 

Dated: December 3, 2018

 

3